Healthcare -
Biotechnology - NASDAQ - US
$ 4.3
7.5 %
$ 258 M
Market Cap
-4.43
P/E
1. INTRINSIC VALUE
Balance Sheet
Aldeyra Therapeutics, Inc.
| Current Assets | 102 M |
| Cash & Short-Term Investments | 101 M |
| Receivables | 0 |
| Other Current Assets | 709 K |
| Non-Current Assets | 2.75 M |
| Long-Term Investments | 0 |
| PP&E | 267 K |
| Other Non-Current Assets | 2.48 M |
| Current Liabilities | 18.6 M |
| Accounts Payable | 180 K |
| Short-Term Debt | 303 K |
| Other Current Liabilities | 18.1 M |
| Non-Current Liabilities | 15 M |
| Long-Term Debt | 15 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Aldeyra Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 250 K |
| Gross Profit | -250 K |
| Operating Expenses | 60.1 M |
| Operating Income | -60.1 M |
| Other Expenses | -4.27 M |
| Net Income | -55.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Aldeyra Therapeutics, Inc.
| Net Income | -55.9 M |
| Depreciation & Amortization | 250 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 7.97 M |
| Change in Working Capital | 5.91 M |
| Others | 5.58 M |
| Free Cash Flow | -43.2 M |
Wall Street Analysts Price Targets
Aldeyra Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for ALDX of $11 , with forecasts ranging from
a
low of
$10 to a high of $12 .
ALDX Lowest Price Target
Wall Street Target
10 USD
132.56%
ALDX Average Price Target
Wall Street Target
11 USD
155.81%
ALDX Highest Price Target
Wall Street Target
12 USD
179.07%
4. DIVIDEND
ANALYSIS
ALDX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Aldeyra Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
4.83 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
127 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data
Aldeyra Therapeutics' Reproxalap is now on its third NDA, which was filed in June 2025. It supposedly fixes prior trial flaws. ALDX believes a potential FDA acceptance could set a PDUFA date for December 2025. After that, AbbVie may pay $100 million upfront and share US profits if Reproxalap wins approval, which should materially de-risk its eventual commercialization.
seekingalpha.com
- 1 week ago
Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced receipt of a Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration (FDA) for ADX-2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma (PVRL), a rare and potentially fatal cancer currently lacking FDA-approved therapy. “Primary vitreoretinal lymphoma is treated today off label with intravitre.
businesswire.com
- 2 weeks ago
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. Per FDA agreement, the only.
businesswire.com
- 4 weeks ago
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in New York, New York. Dr. Brady's conversation with Clara Dong is scheduled to begin at 4:20 p.
businesswire.com
- 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
accessnewswire.com
- 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
accessnewswire.com
- 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
globenewswire.com
- 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
prnewswire.com
- 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
NEW YORK CITY, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
accessnewswire.com
- 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
accessnewswire.com
- 2 months ago
ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Pending Securities Investigation; Contact BFA Law
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc.
accessnewswire.com
- 2 months ago
ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)
NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc.
globenewswire.com
- 2 months ago
8. Profile
Summary
Aldeyra Therapeutics, Inc. ALDX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 258 M
Dividend Yield
0.00%
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Contact
131 Hartwell Avenue, Lexington, MA, 02421
https://www.aldeyra.com
IPO
Date
May 2, 2014
Employees
9
Officers
Laura Nichols
Operations Manager
Dr. Todd C. Brady M.D., Ph.D.
Chief Executive Officer, President & Director
Dr. Stephen G. Machatha Ph.D.
Chief Development Officer
Mr. Michael Alfieri
Head of Finance and Principal Financial & Accounting Officer
David Burke
Head of Investor Relations